Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Mark Tomai
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Living Beings
Anatomy
Procedures
Physiology
Disorders
Sign-in to see full Profile
Network (preview)
15
Miller, Richard
11
Gibson, Sheila
9
Reiter, Michael
8
Vasilakos, John
7
Wagner, Tammy
7
Imbertson, Linda
5
Slade, HB
4
Smith, RM
3
Stanley, MA
3
Tyring, Stephen
3
Gorski, Kevin
3
Smith, MH
3
Pederson, LK
3
Kieper, William
3
Lindh, Jana
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Mark Tomai (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Dumitru Calin D; Antonysamy Mary A; Gorski Kevin S; Johnson Dave D; Reddy Laxma G; Lutterman Jody L; Piri Melissa M; Proksch Joel; McGurran Sean M; Egging Elaine A; Cochran Felicia R; Lipson Kenneth E; Tomai Mark A; Gullikson Gary W
NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
Cancer immunology, immunotherapy : CII 2009;58(4):575-87.
-
2007: Tomai Mark A; Miller Richard L; Lipson Kenneth E; Kieper William C; Zarraga Isidro E; Vasilakos John P
Resiquimod and other immune response modifiers as vaccine adjuvants.
Expert review of vaccines 2007;6(5):835-47.
-
2007: Hammerbeck David M; Burleson Gary R; Schuller Craig J; Vasilakos John P; Tomai Mark; Egging Elaine; Cochran Felicia R; Woulfe Susan; Miller Richard L
Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
Antiviral research 2007;73(1):1-11.
-
2006: Gorski Kevin S; Waller Emily L; Bjornton-Severson Jacqueline; Hanten John A; Riter Christie L; Kieper William C; Gorden Keith B; Miller Jeffrey S; Vasilakos John P; Tomai Mark A; Alkan Sefik S
Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
International immunology 2006;18(7):1115-26.
-
2005: Gerster John F; Lindstrom Kyle J; Miller Richard L; Tomai Mark A; Birmachu Woubalem; Bomersine Shannon N; Gibson Shiela J; Imbertson Linda M; Jacobson Joel R; Knafla Roy T; Maye Peter V; Nikolaides Nickolas; Oneyemi Folakemi Y; Parkhurst Gwen J; Pecore Sharon E; Reiter Michael J; Scribner Lisa S; Testerman Tracy L; Thompson Natalie J; Wagner Tammy L; Weeks Charles E; Andre Jean-Denis; Lagain Daniel; Bastard Yvon; Lupu Michel
Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.
Journal of medicinal chemistry 2005;48(10):3481-91.
-
2005: Gorden Keith B; Gorski Kevin S; Gibson Sheila J; Kedl Ross M; Kieper William C; Qiu Xiaohong; Tomai Mark A; Alkan Sefik S; Vasilakos John P
Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(3):1259-68.
-
2002: Gibson Sheila J; Lindh Jana M; Riter Tony R; Gleason Raymond M; Rogers Lisa M; Fuller Ashley E; Oesterich JoAnn L; Gorden Keith B; Qiu Xiaohong; McKane Scott W; Noelle Randy J; Miller Richard L; Kedl Ross M; Fitzgerald-Bocarsly Patricia; Tomai Mark A; Vasilakos John P
Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Cellular immunology 2002;218(1-2):74-86.
-
2002: Miller R L; Tomai M A; Harrison C J; Bernstein D I
Immunomodulation as a treatment strategy for genital herpes: review of the evidence.
International immunopharmacology 2002;2(4):443-51.
-
2001: Bishop G A; Ramirez L M; Baccam M; Busch L K; Pederson L K; Tomai M A
The immune response modifier resiquimod mimics CD40-induced B cell activation.
Cellular immunology 2001;208(1):9-17.
-
2000: Bishop G A; Hsing Y; Hostager B S; Jalukar S V; Ramirez L M; Tomai M A
Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(10):5552-7.
-
2000: Vasilakos J P; Smith R M; Gibson S J; Lindh J M; Pederson L K; Reiter M J; Smith M H; Tomai M A
Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.
Cellular immunology 2000;204(1):64-74.
-
2000: Tomai M A; Imbertson L M; Stanczak T L; Tygrett L T; Waldschmidt T J
The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.
Cellular immunology 2000;203(1):55-65.
-
2000: Arany I; Tyring S K; Brysk M M; Stanley M A; Tomai M A; Miller R L; Smith M H; McDermott D J; Slade H B
Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts.
Antimicrobial agents and chemotherapy 2000;44(7):1869-73.
-
1999: Ahonen C L; Gibson S J; Smith R M; Pederson L K; Lindh J M; Tomai M A; Vasilakos J P
Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.
Cellular immunology 1999;197(1):62-72.
-
1999: Arany I; Tyring S K; Stanley M A; Tomai M A; Miller R L; Smith M H; McDermott D J; Slade H B
Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%.
Antiviral research 1999;43(1):55-63.
-
1999: Miller R L; Gerster J F; Owens M L; Slade H B; Tomai M A
Imiquimod applied topically: a novel immune response modifier and new class of drug.
International journal of immunopharmacology 1999;21(1):1-14.
-
1999: Chollet J L; Jozwiakowski M J; Phares K R; Reiter M J; Roddy P J; Schultz H J; Ta Q V; Tomai M A
Development of a topically active imiquimod formulation.
Pharmaceutical development and technology 1999;4(1):35-43.
-
1999: Wagner T L; Ahonen C L; Couture A M; Gibson S J; Miller R L; Smith R M; Reiter M J; Vasilakos J P; Tomai M A
Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.
Cellular immunology 1999;191(1):10-9.
-
1998: Tyring S K; Arany I; Stanley M A; Tomai M A; Miller R L; Smith M H; McDermott D J; Slade H B
A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod.
The Journal of infectious diseases 1998;178(2):551-5.
-
1998: Imbertson L M; Beaurline J M; Couture A M; Gibson S J; Smith R M; Miller R L; Reiter M J; Wagner T L; Tomai M A
Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463.
The Journal of investigative dermatology 1998;110(5):734-9.
-
1998: Slade H B; Owens M L; Tomai M A; Miller R L
Imiquimod 5% cream (Aldara).
Expert opinion on investigational drugs 1998;7(3):437-49.
-
1997: Wagner T L; Horton V L; Carlson G L; Myhre P E; Gibson S J; Imbertson L M; Tomai M A
Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463.
Cytokine 1997;9(11):837-45.
-
1995: Tomai M A; Gibson S J; Imbertson L M; Miller R L; Myhre P E; Reiter M J; Wagner T L; Tamulinas C B; Beaurline J M; Gerster J F
Immunomodulating and antiviral activities of the imidazoquinoline S-28463.
Antiviral research 1995;28(3):253-64.
-
1995: Testerman T L; Gerster J F; Imbertson L M; Reiter M J; Miller R L; Gibson S J; Wagner T L; Tomai M A
Cytokine induction by the immunomodulators imiquimod and S-27609.
Journal of leukocyte biology 1995;58(3):365-72.
-
1995: Gibson S J; Imbertson L M; Wagner T L; Testerman T L; Reiter M J; Miller R L; Tomai M A
Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(6):537-45.
-
1994: Reiter M J; Testerman T L; Miller R L; Weeks C E; Tomai M A
Cytokine induction in mice by the immunomodulator imiquimod.
Journal of leukocyte biology 1994;55(2):234-40.
Sign-in to see more
